the adoptive immunotherapy of human cancer using lymphokine-activated killer ( lak ) cells in combination with high-dose systemic recombinant interleukin-2 ( ril-2 ) has been associated with global changes in several hematological and immunological parameters while imposing profound toxicity on patients .
C0086418
human
C0021756
recombinant interleukin-2